Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPEROR study of zorevunersen in Dravet syndrome
2024-519555-28-00Phase 3Authorised
- Sponsor
- Stoke Therapeutics
- Start
- Jun 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of zorevunersen in Dravet syndrome (2 arms), sponsored by Stoke Therapeutics. Primary endpoint: Percent change from baseline in major motor seizure frequency from Week 16 to Week 28. Planned start Jun 2025; status: authorised.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2024-519555-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519555-28-00.